title: Second chance for dronedarone after recent setback?
authors.forename: Asher
authors.initials: A
authors.lastname: Mullard
mesh_terms: D000083:Acetanilides / Q000008:administration & dosage*; D000638:Amiodarone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D026661:Clinical Trials Data Monitoring Committees; D002986:Clinical Trials as Topic; D000075202:Contraindications; D000077764:Dronedarone; D017277:Drug Approval; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D005060:Europe; D006801:Humans; D010879:Piperazines / Q000008:administration & dosage*; D000069458:Ranolazine; D026941:Sodium Channel Blockers / Q000008:administration & dosage*; D016019:Survival Analysis; D014481:United States
chemical_list: D000083:Acetanilides; D000889:Anti-Arrhythmia Agents; D010879:Piperazines; D026941:Sodium Channel Blockers; D000069458:Ranolazine; D000077764:Dronedarone; D000638:Amiodarone